Αρχική World News Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable to... World News Immune Checkpoint Inhibitor-Based Systemic Therapy Combinations for Patients with HCC Amenable to TACE Από Ogkologos - 15 Ιανουαρίου, 2025 1000 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the EMERALD-1 and LEAP-012 studies Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR The Nobel Prize in Chemistry 2020 was Awarded “for the Development... 12 Οκτωβρίου, 2020 Does Sugar Cause Cancer? 9 Νοεμβρίου, 2021 England slips further off-track for smokefree 2030 target 29 Δεκεμβρίου, 2022 FDA Approves Sodium Thiosulfate to Reduce the Risk of Ototoxicity Associated... 13 Οκτωβρίου, 2022 Φόρτωση περισσοτέρων HOT NEWS 177Lu-DOTATATE Shows Promising Efficacy in the Treatment of Patients with Progressive... Sublobar Resection Noninferior to Lobectomy in Terms of DFS Among Patients... Patients with Early-Onset CRC More Often Diagnosed at Advanced Stage of... FDA Grants Accelerated Approval to Loncastuximab Tesirine-lpyl for Large B-Cell Lymphoma